Tehran University of Medical Sciences Iranian Journal of Psychiatry 1735-4587 3 1 2008 03 15 43 45 Firoozeh Raisi Psychiatry and Psychology Research Center, Roozbeh Hospital Tehran University of Medical Sciences, Tehran, Iran Alireza Zahiroddin Department of Psychiatry, Shahid Beheshti University of Medical Sciences, Tehran, Iran Shahin Akhondzadeh Psychiatry and Psychology Research Center, Roozbeh Hospital Tehran University of Medical Sciences, Tehran, Iran Farshad Hashemian School of Pharmacy, Pharmaceutical Sciences Branch, Azad University (IAU), Tehran, Iran Padideh Ghaeli Psychiatry and Psychology Research Center, Roozbeh Hospital Tehran University of Medical Sciences, Tehran, Iran Fiona Baroyant Salmasi School of Pharmacy, Pharmaceutical Sciences Branch, Azad University (IAU), Tehran, Iran Maryam Jazayeri School of Pharmacy, Pharmaceutical Sciences Branch, Azad University (IAU), Tehran, Iran Kazem Golchin Psychiatry and Psychology Research Center, Roozbeh Hospital Tehran University of Medical Sciences, Tehran, Iran Hafez Bajoghli Psychiatry and Psychology Research Center, Roozbeh Hospital Tehran University of Medical Sciences, Tehran, Iran Susan Afghah Department of Psychiatry, Behzisti University of Welfare and Rehabilitation, Tehran, Iran 2015 10 17 Objective: To study the effects of a high dose alpha-tocopherol on serum total cholesterol (TC), triglyceride (TG), and the high density lipoprotein (HDL) levels of patients with schizophrenia receiving olanzapine. Method: Thirty six adults diagnosed with schizophrenia based on DSM-IV who were taking olanzapine for a minimum of thirty days entered this eight-week, double blind, placebo-controlled study. Patients were randomized to receive alpha-tocopherol 400IU or placebo capsules twice a day for 2 weeks, then three times a day for 6 more weeks. Fasting total cholesterol (TC), triglyceride(TG),and HDL levels were measured at the baseline and weeks 4 and 8. Results: TC, TG and HDL levels did not change significantly during this study. There were no significant differences in TC, TG and HDL levels between the two groups at the baseline and weeks 4 and 8. Conclusion: High-dose vitamin may not improve triglyceride and cholesterol levels in patients who are already on olanzapine. Further studies with greater number of patients and for a longer duration are needed. https://ijps.tums.ac.ir/index.php/ijps/article/view/467 https://ijps.tums.ac.ir/index.php/ijps/article/download/467/491